This is the authors' abstract. We don't add key points for this paper.
The validated, predictive, pan-tumor IRS model can expand PD-(L)1 monotherapy benefit outside currently approved indications.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tomlins et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: